Everything we know about running Monowall — in your hands. No gated PDFs.
Written by the engineers building the runtime, kept honest by CI. The table of contents below shows the surface we're shipping toward — full docs open to design partners.
Request Design-Partner Access →curl https://api.monowall.ai/v1/intents \
-H "Authorization: Bearer $MW_TOKEN" \
-d '{
"intent": "Create a hardened
VPC in eu-west-1.",
"approvers": ["sec","infra"]
}'
Every endpoint generates from the same OpenAPI source the platform serves. Typed clients planned for Go, Python, TypeScript, Rust, and Java. Currently in private beta with design partners.
A single-tenant Brain composes intent into IaC. A regional Muscle Agent applies it under sandboxed credentials. A Policy plane gates every step. KMS-isolated state, signed transitions, no shared blast radius.
Request The 32-page PDF →┌───────────────┐ ┌────────────────┐ ┌──────────────┐
│ Operator │───▶│ Brain (HQ) │───▶│ Policy │
│ (Slack/UI) │ │ intent → spec │ │ verdict │
└───────────────┘ └────────┬───────┘ └──────┬───────┘
│ │
spec + verdict decision log
▼ ▼
┌────────────────┐ ┌──────────────┐
│ Muscle Agent │───▶│ Audit Chain │
│ (your VPC) │ │ notarized │
└────────┬───────┘ └──────────────┘
│
provider APIs
▼
[AWS] [GCP] [Azure]
We're pre-audit and honest about it. The grid on the right is what we're designing toward; the list below is what's already available on request. We'd rather tell you what we don't have than mark a checkbox we can't back.
Targets only — none audited yet. The product is built so these audits are achievable, not assumed.
When we ship, releases will land here with the merged PRs and policy delta. We're in private beta now — design partners get changelog access directly.
We're shipping with a small cohort of design partners. Public changelog opens at GA — currently working through the pipeline, governance, and audit-chain surfaces in that order.
Subscribe To Updates →Production status page opens at GA. Design partners get a private status feed and incident notifications today.
Targets at GA · 99.9% Brain · 99.9% Muscle · multi-region active-active